For research use only. Not for therapeutic Use.
GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1].
GSK360A (30 mg/kg i.g.) improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction[1].
| Catalog Number | R054987 |
| CAS Number | 931399-19-8 |
| Synonyms | 2-[[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid |
| Molecular Formula | C17H17FN2O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H17FN2O5/c18-10-3-4-12-11(7-10)15(23)14(16(24)19-8-13(21)22)17(25)20(12)6-5-9-1-2-9/h3-4,7,9,23H,1-2,5-6,8H2,(H,19,24)(H,21,22) |
| InChIKey | TYHRZQVUPPODPT-UHFFFAOYSA-N |
| SMILES | C1CC1CCN2C3=C(C=C(C=C3)F)C(=C(C2=O)C(=O)NCC(=O)O)O |
| Reference | [1]. Bao W, et, al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. |
